PSMA scan for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- Your triple-negative breast cancer has spread (metastatic) and is getting worse
- You are able to do daily activities with some help (ECOG score 0–2)
- You have not had any other cancer recently that needs treatment
- You are not pregnant or breastfeeding
- You have not used another experimental treatment in the past 30 days
- You have tumors that can be seen on a regular scan or brain MRI
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This study looks at how well a special scan (PSMA PET/CT) works for people with cancers other than prostate cancer. If your doctor already scheduled this scan for your care, you may be able to help researchers learn more about its accuracy.
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
This study looks at a PSMA-targeted PET/CT scan using 68Ga-PSMA-617 for tumors that show a specific marker (PSMA). It’s meant to help confirm or evaluate suspected or known PSMA-expressing tumors in real-life clinical practice.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.